PD-L1 antibody (Extracellular Domain) (Biotin)

Catalog No. ABIN6992233

This Mouse Monoclonal antibody specifically detects PD-L1 in ELISA. It exhibits reactivity toward Human.

Quick Overview for PD-L1 antibody (Extracellular Domain) (Biotin) (ABIN6992233)

Target: PD-L1 (CD274 (PD-L1))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This PD-L1 antibody is conjugated to Biotin

Application: ELISA

Clone: 8E12

Product Details anti-PD-L1 Antibody (Biotin)

Binding Specificity: Extracellular Domain

Purification: PD-L1 Antibody is supplied as protein A purified IgG1.

Immunogen: PD-L1 antibody was raised against the extracellular domain of human PD-L1.

Isotype: IgG1

Application Details

Application Notes: PD-L1 antibody can be used for as detection antibody in Sandwich Elisa at 1 μ,g/mL.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Buffer: PD-L1 Antibody is supplied in PBS containing 1 % BSA and 0.02 % sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C,4 °C

Storage Comment: PD-L1 antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Target Details for PD-L1

Target: PD-L1 (CD274 (PD-L1))

Alternative Name: PDL1

Background: PD-L1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC) (1). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC (2). PD-1 can bind two different but related ligands, PD-L1 and PD-L2. PD-L1 is a B7-related protein that inhibits cell-mediated immune responses by reducing the secretion of IL-2 and IL-10 from memory T cells (3). This suggests that PD-L1 may be useful in reducing allogenic CD4+ memory T-cell responses to endothelial cells, thereby reducing the likelihood of host immune responses to allografts. PD-L1 also functions as an immune checkpoint protein, and multiple anti-PD-L1 antibodies are currently in phase II and III clinical trials, with one antibody already approved for the treatment of cancer (4).

Gene ID: 29126

NCBI Accession: NP_054862

UniProt: Q9NZQ7

Pathways: Cancer Immune Checkpoints